c-Met/HGFR
c-Met/HGFR inhibitors target the Hepatocyte Growth Factor Receptor (c-Met), a tyrosine kinase involved in cellular processes such as growth, motility, and morphogenesis. c-Met signaling is implicated in cancer progression, metastasis, and resistance to therapies. Inhibiting c-Met can disrupt tumor growth and spread, making these inhibitors valuable in cancer research. At CymitQuimica, we offer c-Met/HGFR inhibitors to support your research in oncology, metastasis, and targeted cancer therapies.
Products of "c-Met/HGFR"
Sort by
Capmatinib xHCl
CAS:Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50Formula:C23H18ClFN6OPurity:98.62% - 99.12%Color and Shape:SolidMolecular weight:448.89Telisotuzumab
CAS:Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Purity:SDS-PAGE:96.4%;SEC-HPLC:98.5%Color and Shape:LiquidMolecular weight:145.50 kDaTerevalefim
CAS:Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.Formula:C9H8N2SPurity:99.53%Color and Shape:SolidMolecular weight:176.24Ref: TM-T37596
1mg56.00€5mg119.00€10mg210.00€25mg369.00€50mg537.00€100mg750.00€500mg1,539.00€1mL*10mM (DMSO)119.00€BMS 777607
CAS:BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3. BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.Formula:C25H19ClF2N4O4Purity:100% - 99.89%Color and Shape:SolidMolecular weight:512.89Ref: TM-T2699
1mg35.00€5mg79.00€10mg124.00€25mg217.00€50mg359.00€100mg533.00€500mg1,169.00€1mL*10mM (DMSO)92.00€Tyrosine kinase inhibitor
CAS:Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.Formula:C31H31FN6O5Purity:98%Color and Shape:SolidMolecular weight:586.61CSF1R-IN-2
CAS:CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).Formula:C20H20FN7O2Purity:99.29%Color and Shape:SolidMolecular weight:409.42C-Met inhibitor D9
CAS:C-Met inhibitor D9 is a c-Met kinase inhibitor.Formula:C17H15N3O2Purity:97%Color and Shape:SolidMolecular weight:293.32BMS-794833
CAS:BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.Formula:C23H15ClF2N4O3Purity:98% - 99.69%Color and Shape:SolidMolecular weight:468.84Ref: TM-T2419
1mg42.00€2mg52.00€5mg88.00€10mg150.00€25mg296.00€50mg537.00€100mg772.00€1mL*10mM (DMSO)95.00€LMTK3-IN-1
CAS:Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.Formula:C18H11F3N4OPurity:100%Color and Shape:SoildMolecular weight:356.3SCR-1481B1
CAS:SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitorFormula:C32H40ClF2N6O13PPurity:98.07%Color and Shape:SolidMolecular weight:821.12Ref: TM-T5349
1mg38.00€2mg49.00€5mg79.00€10mg119.00€25mg210.00€50mg350.00€100mg522.00€1mL*10mM (DMSO)107.00€XL092
CAS:XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.Formula:C29H25FN4O5Purity:98.60%Color and Shape:SolidMolecular weight:528.53Ensartinib hydrochloride
CAS:Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of knownFormula:C26H29Cl4FN6O3Purity:98.73%Color and Shape:SolidMolecular weight:634.36Ref: TM-T22324
1mg66.00€2mg93.00€5mg144.00€10mg227.00€25mg464.00€50mg677.00€100mg938.00€1mL*10mM (DMSO)188.00€JNJ-38877605
CAS:JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.Formula:C19H13F2N7Purity:97.04% - 98.27%Color and Shape:SolidMolecular weight:377.35EGFR-IN-8
CAS:EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLCFormula:C32H23ClF3N7O4Purity:97.45%Color and Shape:SolidMolecular weight:662.02Glesatinib hydrochloride
CAS:Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.Formula:C31H28ClF2N5O3S2Purity:98%Color and Shape:SolidMolecular weight:656.16NPS-1034
CAS:NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.Formula:C31H23F2N5O3Purity:98.48%Color and Shape:SolidMolecular weight:551.54Ningetinib Tosylate
CAS:Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Formula:C38H37FN4O8SPurity:99.93%Color and Shape:SolidMolecular weight:728.79PF-04217903 phenolsulfonate
CAS:PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Formula:C25H22N8O5SPurity:98%Color and Shape:SolidMolecular weight:546.56Savolitinib
CAS:Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).Formula:C17H15N9Purity:98.12%Color and Shape:SolidMolecular weight:345.36Ref: TM-TQ0210
1mg49.00€2mg64.00€5mg92.00€10mg131.00€25mg210.00€50mg373.00€100mg567.00€1mL*10mM (DMSO)97.00€SAR125844
CAS:SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)Formula:C25H23FN8O2S2Purity:98.39%Color and Shape:SolidMolecular weight:550.63Ref: TM-T5467
1mg35.00€5mg79.00€10mg116.00€25mg227.00€50mg364.00€100mg588.00€200mg833.00€1mL*10mM (DMSO)96.00€
